Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 15
- 13F valueReported value at the end of Q2 2026
- $4.99M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ESLA, Q2 2026
No superinvestor reported holding ESLA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Estrella Immunopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 (view filing) | Sep 11-Oct 7, 2025 | 230 daysLate | Xu JiandongChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.10K | $1.30 | +$1.43K | +0.4%265.5K after | 2 lots |
| Apr 29, 2026 (view filing) | Sep 22, 2025 | 219 daysLate | Xu JiandongChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | $1.16 | +$1.16K | +6.4%16.7K after | |
| Mar 17, 2022 (view filing) | Mar 4 | 13 daysLate | Li JianweiCo-Chief Executive Officer | PPurchase | +142.0K | $314,700.00 | +$44.7B | +12.8%1.25M after | Price outlier |
Top 10 13F holders, Q2 2026
The largest institutional positions in Estrella Immunopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,975,220 | $4.13M | 0.11% | −123,780−3.0% | Reduced |
| Vanguard Capital Management LLC | 416,852 | $433.5K | 0.00% | +34,383+9.0% | Added |
| Geode Capital Management, LLC | 141,321 | $147.0K | 0.00% | −16,164−10.3% | Reduced |
| Vanguard Fiduciary Trust Co | 64,921 | $67.5K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 52,033 | $54.1K | 0.00% | +12,143+30.4% | Added |
| State Street Corp | 43,252 | $45.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 39,100 | $40.7K | 0.00% | −23,695−37.7% | Reduced |
| Northern Trust Corp | 34,861 | $36.3K | 0.00% | +15,237+77.6% | Added |
| US Bancorp | 20,000 | $20.8K | 0.00% | +3,096+18.3% | Added |
| Tower Research Capital LLC (TRC) | 3,308 | $3.44K | 0.00% | −1,551−31.9% | Reduced |